Xiamen Amoytop Biotech Co Ltd (688278) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xiamen Amoytop Biotech Co Ltd (688278) has a cash flow conversion efficiency ratio of 0.197x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥332.29 Million ≈ $48.63 Million USD) by net assets (CN¥1.69 Billion ≈ $247.28 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Xiamen Amoytop Biotech Co Ltd stock valuation for the company's overall valuation and market capitalisation.
Xiamen Amoytop Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Xiamen Amoytop Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Xiamen Amoytop Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xiamen Amoytop Biotech Co Ltd ranked by their cash flow conversion efficiency. Explore Xiamen Amoytop Biotech Co Ltd cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mangalore Refinery and Petrochemicals Limited
NSE:MRPL
|
0.305x |
|
Hong Ri Da Technology Co. Ltd. A
SHE:301285
|
N/A |
|
Shanghai Huace Navigation Technology Ltd
SHE:300627
|
-0.017x |
|
CRRC Corporation Limited
F:C2L
|
-0.034x |
|
SEB SA
PA:SK
|
0.051x |
|
CoreCivic Inc
NYSE:CXW
|
0.092x |
|
Orion Oyj A
HE:ORNAV
|
0.086x |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
0.004x |
Annual Cash Flow Conversion Efficiency for Xiamen Amoytop Biotech Co Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Xiamen Amoytop Biotech Co Ltd from 2016 to 2024. View 688278 stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.55 Billion ≈ $373.63 Million |
CN¥430.63 Million ≈ $63.02 Million |
0.169x | -38.20% |
| 2023-12-31 | CN¥1.88 Billion ≈ $274.58 Million |
CN¥512.10 Million ≈ $74.94 Million |
0.273x | +5.78% |
| 2022-12-31 | CN¥1.41 Billion ≈ $205.98 Million |
CN¥363.16 Million ≈ $53.14 Million |
0.258x | +27.61% |
| 2021-12-31 | CN¥1.16 Billion ≈ $169.93 Million |
CN¥234.78 Million ≈ $34.36 Million |
0.202x | +118.40% |
| 2020-12-31 | CN¥1.00 Billion ≈ $146.39 Million |
CN¥92.61 Million ≈ $13.55 Million |
0.093x | -57.69% |
| 2019-12-31 | CN¥563.55 Million ≈ $82.47 Million |
CN¥123.30 Million ≈ $18.04 Million |
0.219x | +22.53% |
| 2018-12-31 | CN¥499.26 Million ≈ $73.06 Million |
CN¥89.15 Million ≈ $13.04 Million |
0.179x | +856.57% |
| 2017-12-31 | CN¥483.26 Million ≈ $70.72 Million |
CN¥-11.41 Million ≈ $-1.67 Million |
-0.024x | -126.59% |
| 2016-12-31 | CN¥478.09 Million ≈ $69.96 Million |
CN¥42.43 Million ≈ $6.21 Million |
0.089x | -- |
About Xiamen Amoytop Biotech Co Ltd
Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China. The company provides solutions for diseases, such as viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is based in Xiamen, China.